<DOC>
	<DOCNO>NCT01523522</DOCNO>
	<brief_summary>This project aim offer autologous muscle-derived progenitor cell injection efficient mini-invasive surgical therapy would simple patient could use majority case , include young woman post-partum . This approach may provide efficient tissue repair striate anal sphincter permit exist therapy . This innovative therapy may ultimately proposed failure common treatment high-risk invasive surgical intervention . Besides , injection muscle-derived progenitor cell animal show encouraging result sphincter function assess ex vivo . Hence , high benefit may expect approach .</brief_summary>
	<brief_title>Autologous Myoblast Intrasphincteric Injection Fecal Incontinence</brief_title>
	<detailed_description>verification information inclusion criterion . patient randomize treatment placebo arm receive injection . evaluation function quality life realize . period 6 month , patient placebo arm receive injection myoblasts preserve .</detailed_description>
	<mesh_term>Fecal Incontinence</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Inclusion criterion age 20 65 year severe fecal incontinence least three month Jorge et Wexner score ≥ 10 incontinence refractory medical treatment reeducation least three month incontinence due lesion external anal sphincter incontinence without significant anal sphincter rupture rupture ≤ 30 % circumference assess endoanal ultrasonography integrity internal anal sphincter fecal incontinence normal rectum capacity ( maximum tolerable volume ≥ 150 ml assess anorectal manometry ) fecal incontinence without associate rectal static disorder defecoMRI fecal incontinence without bilateral complete neuropathy assess electrophysiology Exclusion criterion fecal incontinence rupture &gt; 30 % external anal sphincter fecal incontinence bilateral lesion sacral nerve Crohn 's disease ulcerative colitis unstable type 1 type 2 diabetes myopathy peripheral central neurological disease treatment laxative , suppository enema practice anal intercourse except stop study treatment immunosuppressive cytostatic drug , CoA HMG reductase inhibitor , morphine derivative treatment constipation rectal dyschesia pregnancy breastfeeding , lack effective contraception study ( female ) allergy antibiotic ( cephalexin , metronidazole )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Fecal incontinence</keyword>
	<keyword>Myoblast</keyword>
	<keyword>Surgery</keyword>
</DOC>